Programming CAR-T cells to kill cancer
- 11 June 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Biomedical Engineering
- Vol. 2 (6), 377-391
- https://doi.org/10.1038/s41551-018-0235-9
Abstract
T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour antigens have led to high complete response rates in patients with haematologic malignancies. Despite this early success, major challenges to the broad application of CAR-T cells as cancer therapies remain, including treatment-associated toxicities and cancer relapse with antigen-negative tumours. Targeting solid tumours with CAR-T cells poses additional obstacles because of the paucity of tumour-specific antigens and the immunosuppressive effects of the tumour microenvironment. To overcome these challenges, T cells can be programmed with genetic modules that increase their therapeutic potency and specificity. In this Review Article, we survey major advances in the engineering of next-generation CAR-T therapies for haematologic cancers and solid cancers, with particular emphasis on strategies for the control of CAR specificity and activity and on approaches for improving CAR-T-cell persistence and overcoming immunosuppression. We also lay out a roadmap for the development of off-the-shelf CAR-T cells.Keywords
This publication has 224 references indexed in Scilit:
- Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in GlioblastomaMolecular Therapy, 2013
- TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer ImmunotherapyMolecular Therapy Nucleic Acids, 2013
- Targeting stroma to treat cancersSeminars in Cancer Biology, 2012
- PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen ReceptorMolecular Therapy, 2011
- MicroRNA-29 Regulates T-Box Transcription Factors and Interferon-γ Production in Helper T CellsImmunity, 2011
- MicroRNAs in immune regulation—Opportunities for cancer immunotherapyThe International Journal of Biochemistry & Cell Biology, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor EradicationMolecular Therapy, 2010
- Hybrid Lentivirus-transposon Vectors With a Random Integration Profile in Human CellsMolecular Therapy, 2009
- Tumor immunotherapy across MHC barriers using allogeneic T-cell precursorsNature Biotechnology, 2008